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Abstract 
 
The T allele of the human dopamine D2 receptor (DRD2) gene C957T polymorphism 
is associated with reduced mRNA translation and stability. This results in decreased 
dopamine induced DRD2 upregulation and decreased in-vivo D2 dopamine binding. 
Conversely, the C allele of the C957T polymorphism is not associated with such 
changes in mRNA leading to increased DRD2 expression. PET and post-mortem 
binding studies show that schizophrenia is often associated with increased DRD2 
availability. We report that on the basis of comparing the frequencies of the C/C and 
T/T genotypes of 153 patients with schizophrenia and 148 controls that schizophrenia 
is associated with the C/C genotype. The C957T shows a population attributable risk 
for schizophrenia of 24% and an attributable risk in those with schizophrenia of 42%. 
Increased expression of D2 receptors associated with the C allele is likely to be 
important in the underlying pathophysiology of at least some forms of schizophrenia. 
Enhanced understanding of schizophrenia afforded by this finding may lead to 
advances in treatment and prevention. 
 
Author Keywords: Association; Dopamine; D2 receptor; Genetic; Schizophrenia, 
C957T. 
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1. Introduction 
 
Schizophrenia is a common, chronic, disabling illness with an incidence of 15 new 
cases per 100,000 population per year with an onset typically in late adolescence or 
early adulthood (Kelly et al., 2003). Additionally, first-degree relatives show 
cognitive deficits from childhood (Niendam et al., 2003) into adulthood (MacDonald, 
2003) indicating the presence of pre-morbid markers of the disorder.  Siblings of 
schizophrenic patients exhibit an abnormal fMRI response in the dorsolateral 
prefrontal cortex resulting in information processing deficits (Callicott et al., 2003).  
Both those with schizophrenia and their unaffected siblings show reductions in 
hippocampal volume and a hippocampal shape deformity (Tepest et al., 2003). 
Decreased temporoparietal P300 amplitude and increased frontal P300 amplitude are 
also found in both schizophrenic patients and their siblings (Winterer et al., 2003)   
 
Twin study data reveal that the heritability of schizophrenia is about 80% (Sullivan et 
al., 2003).  The high genetic risk for schizophrenia has led to considerable research 
efforts aimed at the identification of susceptibility genes, including large linkage 
studies (for example; Mowry et al., 2004).  Significant linkages with specific 
chromosomal regions have been identified (Owen et al., 2004). Despite this progress, 
the conclusive identification of specific molecular genetic aetiological factors in the 
pathogenesis of schizophrenia that account for significant risk has not yet occurred. 
    
Several lines of evidence implicate the dopamine D2 receptor (DRD2) gene as a 
candidate gene for susceptibility to schizophrenia.  All antipsychotic medications are 
either antagonists or partial agonists of the dopamine D2 receptor, which is the 
primary site of action for these medications (Miyamoto et al., 2004). Schizophrenic 
symptoms are ameliorated by a reduction in dopamine D2 receptor function.  
Additionally, neuroimaging evidence indicates that schizophrenic patients have 
increased brain dopamine D2 receptor density (Seeman & Kapur, 2000). For example, 
untreated patients with schizophrenia and controls pharmacologically depleted of 
endogenous dopamine have been studied using in-vivo measurements of D2 receptor 
availability made both before and after dopamine depletion (Abi-Dargham, et al., 
2000). The schizophrenic subjects demonstrated a larger increase in D2 receptor 
availability post-dopamine depletion than controls.  These data suggest that 
schizophrenia is characterised by a physiological state of increased D2 receptor 
availability.  
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Association studies of polymorphisms of the DRD2 have generally yielded results 
that are just significant, are inconsistent across different ethnic groups, or fail to reach 
significance (see Table 1 for a summary of studies published in English). The most 
consistent association identified in Table 1 is between the A2 allele of the Taq 1A 
polymorphism of the DRD2 gene and schizophrenia (Dubertret, et al., 2001, 2004) 
however this association is of a small magnitude. The -141 C Ins/del has shown a 
significant association with schizophrenia; however these associations have been in 
the opposite direction in Japanese and Scandinavian participants (Arinami, et al., 
1997; Ohara et al., 1998; Jonsson et al., 1999) when compared to their British 
counterparts (Breen et al., 1999).  
 
INSERT TABLE 1 ABOUT HERE 
 
A synonymous polymorphism in the DRD2 gene, the C957T is in linkage 
disequilibrium with Taq 1A. The C957T has been associated with in vitro functional 
effects (Duan et al., 2003) that have considerable potential implications for genetic 
risk for schizophrenia. The T allele is associated with decreased translation of DRD2 
mRNA, decreased DRD2 mRNA stability and markedly diminished dopamine 
induced upregulation of D2 receptors. Furthermore, the C957T affects striatal 
dopamine D2 binding in healthy subjects (Hirvonen et al., 2004). Subjects 
homozygous for the C allele (C/C) have the highest striatal binding. Heterozygous 
individuals (C/T) have intermediate binding whilst individuals homozygous for the T 
allele (T/T) have the lowest binding. As schizophrenia is associated with increased D2 
availability we postulated that the C/C genotype, which is associated with a greater 
expression of D2 receptors, would be found more frequently in schizophrenia. 
Conversely, the T/T genotype would be protective against schizophrenia and have a 
decreased frequency amongst schizophrenic patients. The C/T genotype, with 
intermediate binding, was postulated to be found at the same frequency in both 
schizophrenic and control subjects. 
  
2. Method 
 
2.1. Subjects 
 
To evaluate the frequency of the C and T alleles of the C957T polymorphism in 
unrelated Caucasian patients with schizophrenia, we genotyped 153 patients with 
schizophrenia and 148 Caucasian controls. To avoid population stratification bias 
both control and clinical subjects were of mixed Northern European origin from the 
same breeding population. The study is more than sufficiently powered with an N = 
301 to detect a small-medium effect in allelic frequency between the two groups. For 
example, to detect a real difference in allelic frequency with a power of 0.8 (α = 0.05), 
d.f. = 1, Lambda = 7.88, and an effect size of 0.2;  a minimum sample of 197 would 
be necessary (Cohen, 1988).  
 
Inclusion criteria for patients were being aged between 18 and 65 years and having a 
stable DSM IV diagnosis of schizophrenia. These patients had no other psychiatric 
disorder, including schizoaffective disorder, major depressive episode with psychotic 
features, or substance misuse. There were 20 females and 133 males in the group 
diagnosed with schizophrenia. They had a mean age of 36.2 years (s.d.+ 12.3 years). 
Patients were being treated at the Royal Brisbane and Women's Hospital, The Park 
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Psychiatric Unit and the Valley Community Mental Health Centre. No patients were 
treated with regular antidepressant, anxiolytic or mood stabilising psychotropic 
medication. The sample was composed of 69 inpatients and 84 outpatients.  
 
While the patients did not meet criteria for a substance dependence disorder self-
report data indicated that 47 patients reported binge drinking (defined as any drinking 
in the last 12 months where alcohol consumption exceeded 40 grams per day for 
women and 60 grams per day for men). A significant number of patients (N=74) also 
described severe past psychological distress as indicated by a suicide attempt. A total 
of 121 patients were able to provide information on self-reported biological family 
history of psychiatric illness with 82 patients reporting a positive history of 
schizophrenia. As such, the sample represents a group with schizophrenia who have 
minimal psychiatric comorbidity but contains significant proportions of individuals 
with a relatively severe history and/or a familial risk for psychosis.  
 
There were 43 females and 105 males in the control group with a mean age of 36.8 
years (s.d. + 12.8 years). The control group was composed of hospital nursing and 
medical staff as well as university staff and students. Ethics approval was obtained 
from the various institutions involved. 
  
2.2. Genotyping 
 
Genotyping was performed by kinetic real-time PCR using the Applied Biosystems 
7000 sequence detection system (Applied Biosystems, Foster City, CA, USA).  
Sequence specific primers were designed for the C allele (5′-
ATGGTCTCCACAGCACTCTC-3′), the T allele (5′-
ATGGTCTCCACAGCACTCTT-3′) and a common reverse primer (5′-
CATTGGGCATGGTCTGGATC-3′).  A total of 5-10 ng of genomic DNA was 
amplified in 1 x SYBR green PCR master mix (Applied Biosystems) containing 0.4 
µM of allele specific forward primer and 0.4 µM of common reverse primer in a 25 
µL volume.  Amplification conditions were; 50°C for 2 min, 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.  A cycle time (Ct) value 
was obtained by setting the threshold during geometric phase of amplification and 
scored relative to the ∆Ct generated between the matched and mismatched primer 
pairs. 
 
2.3 Statistical analysis  
 
Chi-squared statistic was employed to evaluate differences in frequency of the C and 
T alleles of the C957T polymorphism found in the control and schizophrenic groups. 
 
3. Results 
 
The observed frequency of the C and T alleles in schizophrenic and control 
individuals showed a significant difference in allele frequency between the two 
groups with the C allele being found more frequently in the schizophrenia group 
(χ2=11.219,p=0.0008, Table 2).  The genotypes of both groups are displayed in Table 
3. As the maximum functional difference in binding occurs between the C/C and T/T 
genotypes the frequency of C and T alleles in homozygotes were compared in the 
schizophrenia and control groups. The C allele was significantly associated with 
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schizophrenia (χ2=20.46, p<0.00001). Upon inspection of Table 3 it is evident that 
there is no difference in the frequency of C/T heterozygotes.  
 
Both schizophrenic and control groups are in Hardy-Weinberg equilibrium based on 
the respective allele frequencies of each group. Assuming a prevalence of 
schizophrenia of 1% of the population, the population attributable genetic risk for this 
polymorphism is 24% (CI=10%-35%). The attributable risk in the schizophrenic 
population is 42% (CI=20%-58%)(Abramson & Gahlinger, 2001)  
 
 
 
 
Table 2.  Allele frequencies of the C and T alleles of the C957T polymorphism in 
schizophrenic and control groups.  
 
                           Allele Frequency 
 C T 
Controls 
n=296 124 (41.9%) 172 (58.1%)
Schizophrenia*   
n=306 171 (55.5%) 137 (44.5%)
* χ2 = 11.219; P = 8 x 10-4 
 
 
Table 3. Genotype frequencies of the C/C, C/T, and T/T alleles of the C957T 
polymorphism in schizophrenic and control groups. 
 
                              Genotype frequency 
 C/C C/T T/T 
Controls  
n=148 
27 
(18.2%) 
70 
(47.3%) 51 (34.5%) 
Schizophrenia 
n=153 
48 
(31.2%) 
75 
(48.7%) 31 (20.1%) 
 
 
 
 
 
4. Discussion 
 
We report an association between C957T variants and schizophrenia that exceeds the 
magnitude of other findings examining DRD2 polymorphisms (see Table 1). These 
results suggest that in addition to the D2 receptor being centrally involved in the 
action of antipsychotic medication (Kapur & Mamo, 2003), genetically determined 
differences in D2 upregulation are at least partially involved in the underlying 
pathophysiology of schizophrenia. 
 
When our results are considered together with functional studies of the C957T 
polymorphism (Duan et al., 2003) a scientifically plausible link can be found between 
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gene function and the underlying pathophysiology of schizophrenia.  The decreased 
translation and stability of mRNA and consequent reduction in dopamine induced 
upregulation of DRD2 expression produced by the T/T genotype appears to result in a 
lower likelihood of developing schizophrenia. The C/C genotype may constitute a risk 
factor for this disorder. These findings are consistent with the known association of 
both schizophrenia and the C/C genotype with increased striatal D2 receptor 
availability (eg, Miyamoto et al., 2004; Seeman & Kapur, 2000; Hirvonen et al., In 
press). 
 
A meta-analysis of post-mortem and in-vivo studies of D2 receptor density in brains 
of schizophrenic subjects conducted between 1980 and 1996 revealed that increased 
D2 receptor binding could only be found in 70% of cases. In 30% of patients D2 
receptor binding could not be distinguished from that found in normal controls 
(Zakzanis & Hansen, 1998). Although increased binding is found in the majority of 
people with schizophrenia a significant proportion do not exhibit this finding. 
Furthermore, in a recent study of ten drug naïve patients with schizophrenia, thalamic 
D2 receptor binding was reduced when compared with that of unaffected controls 
(Yasuno et al., 2004).  In our sample, 20.1% of patients with schizophrenia have the 
T/T genotype and, based on in vitro (Duan et al, 2003) and in-vivo data (Hirvonen et 
al., 2004) have decreased D2 binding. Equally 79.9% will have intermediate or 
increased binding (C/C and C/T genotypes). In the control group, 34.5% have 
decreased binding with 65.5% having intermediate or increased binding. These data 
are consistent with the observation that although D2 receptor binding tends to be 
increased in schizophrenia this marker is not specific for the illness in general. Given 
this lack of specificity, neuroimaging studies of small numbers of patients and 
controls have the potential to report unreliable results depending on the proportion of 
genotypes selected. 
 
Our data also suggest involvement of other mechanisms and genes in the pathogenesis 
of schizophrenia. Evidence is accumulating that in addition to hyperstimulation of 
striatal D2 receptors, deficient stimulation of prefrontal D1 receptors and N-methyl-d-
aspartate (NMDA) hypofunction are all associated with this disorder (Laurelle, et al., 
2003). These findings are not mutually exclusive, as functional links exist between the 
systems involved. Upregulation of prefrontal D1 receptors may result from dopamine 
deficiency in the cortex leading to the negative and cognitive symptoms of 
schizophrenia whilst subcortical excess of dopamine is postulated to be responsible 
for positive symptoms. Furthermore, dopamine D2 receptors inhibit NMDA induced 
glutamate release in the substantia nigra (Marti, et al., 2002) and transactivate a 
receptor tyrosine kinase to inhibit NMDA receptor transmission in pyramidal neurons 
(Kotecha, et al 2002). Increased translation and stability of DRD2 mRNA and 
consequent augmentation of in-vivo dopamine D2 expression in subjects with the C/C 
genotype may result in NMDA hypofunction.  Conversely the T/T genotype, which is 
associated with decreased in vitro translation and stability of DRD2 mRNA, as well as 
reduced in-vivo dopamine D2 receptor expression, can produce reduced inhibition of 
NMDA receptors. This allele is found less commonly in patients with schizophrenia. 
The tendency for high dopamine D2 binding to be associated with schizophrenia may 
be at least partly responsible for the NMDA hypofunction found in this disorder.  
 
A recent review describes the lack of convergence between studies of gene expression 
conducted to date and neuropathology in schizophrenia (Harrison & Weinberger, In 
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press). Specifically, the link between gene function and the psychopathophysiology of 
schizophrenia has not been demonstrated with a range of putative susceptability genes 
including neuregulin, dysbindin, DISC1, RGS4, GRM3, G72. Harrison & Weinberger 
(in press) state that, with the possible exception of COMT, no causative mechanism to 
explain why these genes predispose to schizophrenia has been identified. Our findings 
offer a scientifically plausible and theory driven link between gene function and the 
known psychopathophysiology associated with schizophrenia. Indeed, Harrison & 
Weinberger (in press) state that "characterisation of a core molecular pathway and a 
"genetic cytoarchitecture" would be a profound advance in the understanding of 
schizophrenia which may also have equally significant therapeutic implications".  
 
Antipsychotic medication depends on dopamine D2 antagonism and may be more 
efficacious in C/C patients who have an enhanced capacity for dopamine upregulation 
compared to T/T homozygous patients.  This marker may be a useful focus for 
pharmacogenetic research. Environmental influences such as illicit drug use and stress 
are also known to be important in the aetiology of schizophrenia and stimulate 
dopamine release (Howes et al., 2004).  Individuals with the C/C genotype may be 
more susceptible to such environmental influences as a result increased dopamine D2 
receptor expression and as such this genotype may be a useful marker for studies 
examining the development of schizophrenia. Improving the identification of those 
who may be at increased risk for this disorder, or a specific subgroup of these 
individuals, would allow for the development of effective preventative strategies 
aimed at minimizing such environmental risk.  Knowledge of parental and sibling C/C 
or T/T genotypes is likely to assist family counselling for those with an affected 
family member (Hodgkinson et al., 2001).   
 
Limitations of this study include that the findings cannot be generalised to other 
psychotic disorders, for example schizoaffective disorder or mood disorders with 
psychotic features. The strength of the results is tempered by small sample size and 
this finding needs further replication in a larger sample. Future research should also 
examine whether specific phenotypic characteristics, such as symptom profile, age of 
onset and treatment response is associated with C957T polymorphisms and examine 
the generalisation of this to other ethnic groups..     
 
5. Conclusions. 
The proportion of attributable risk indicates that the C/C genotype of the C957 
polymorphism is a major factor in the heritability of schizophrenia, or for a large sub-
group of those with schizophrenia.  This highly significant result, which is consistent 
with both known in vitro and in-vivo gene function and binding studies, indicates 
likely aetiological pathophysiological significance and is likely to enable major 
advances in diagnosis and treatment. 
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Table 1. Association Studies of DRD2 polymorphisms and schizophrenia 
 
 
Taq 1A Dubertret et al, 
2001  
 
 
Dubertret et al, 
2004 
 
50 patients 
50 controls 
 
 
103 patients 
  83 controls 
A2 Significant  
(only in those with 
an onset over 20 
years of age)  
A2 Significant 
Ser311Cys Itokawa et al 1993 
 
Aranami, et al, 
1994. 
Laurent et al, 1994 
 
Hattori, et al 1994 
 
Kaneshima et al, 
1997. 
Hori, et al,  2001 
  50 patients 
110 controls  
156 patients 
300 controls 
113 patients 
184 controls 
100 patients 
100 controls 
  78 patients 
112 controls 
241 patients  
201 controls 
 
Not significant 
 
Significant 
 
Not significant 
 
Not significant 
 
Not significant 
 
Not significant 
-141C Ins/del Arinami et al, 1997 
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